secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001628280-25-047322
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn Therapeutics advances three degrader programs; ARID1B degrader selectively degrades ARID1B
--------------------------------------------------------------------------------

- Selective ARID1B degrader shows selective binding and degradation, potentially relevant in up to 5% of solid tumors (endometrial, gastric, bladder, NSCLC).
- Selective CBP degrader CBPd-171 advancing to non-GLP toxicology studies in Q4 2025; IND-ready in 2026 for EP300-mutant cancers and ER+ breast cancer.
- Selective EP300 degrader demonstrates efficacy in >70% of hematological malignancies and IMiD-resistant multiple myeloma without thrombocytopenia.
- All three programs leverage novel degrader technology to overcome historical challenges of high homology with ARID1A, CBP/EP300.
- Company hosting virtual investor event on October 30, 2025 at 12 p.m. ET to present data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025047322/0001628280-25-047322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025047322/fhtx-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-047322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer